Cardiovascular disease is the leading cause of death in the Western World

Accounting for more than 17 million deaths p.a. In Europe and the US alone approximately 15-20 million patients a year visit an
Emergency Department (ED) reporting chest pain which must be investigated as possibly caused by a cardiac event.

People in the U.S. died from heart disease, stroke and other cardiovascular diseases in 2013. That’s around one of every three deaths in America.


Every 43 seconds someone in the US
has a heart attack.


Spent on unnecessary admissions
annually in the US alone.

Acute Myocardial Infarction (heart attack, Acute Myocardial Infraction “AMI”) affects all of us at some point in our lives, directly or indirectly, Rapid diagnosis is key; treatment in the first “Golden Hour” being crucial to survival. Equally, early “rule out” of AMI as  the cause of chest pain can save healthcare providers $billions.

Our Mission

Through our Joint Venture ownership in MIDS Medical we are developing MIDS Cardiac™, a cost-effective hand held Point of Care rapid cardiac diagnostic device. MIDS Medical applies patent-protected magnetic nanoparticle detection technology and world-class technical expertise.

Our development targets the delivery of a hand held device to support high sensitivity tests to identify or discount AMI (Heart Attack), with accuracy equal or better than gold standard laboratory tests, within minutes. This will significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain and with suspected Acute Myocardial Infarction.

The system is designed to be used with a minimum of training; by any ER nurse or by paramedics at the scene. We believe such a device will be in universal demand; able to meet a critical medical need and rapidly penetrate a multi-billion dollar market.

MIDS Cardiac™

Rapid detection of very low levels of cardiac markers with a primary focus on troponin I and T, designed to equal or exceed gold standard laboratory levels of accuracy, at the Point of Care.


MIDS Cardiac™ is being developed to deliver the following key features:


Equal or superior to gold standard laboratory high sensitivity assays


Single troponin I or T test within 3 minutes and three panel test (additional cardiac biomarkers within 8 minutes)


A fraction of the cost of laboratory analyzers and results not requiring interpretation from specialized medical personnel


Handheld reader design: automated operation by minimally trained personnel, little manual intervention, digital output with low power usage and connectivity to hospital and health authority IT systems


Detects most cardiac biomarkers at the magnetic nanoparticle level. Examples are troponin T & I, D-dimer, Myoglobin and CK-MB


Requires a tiny finger prick blood sample. Existing AMI tests require anything from 3 to 400 times this amount of blood, causing distress and discomfort to the patient